Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Standard-Dose Intradermal Influenza Vaccine Elicits Cellular Immune Responses Similar to Those of Intramuscular Vaccine in Men With and Those Without HIV Infection.

Amoah S, Mishina M, Praphasiri P, Cao W, Kim JH, Liepkalns JS, Guo Z, Carney PJ, Chang JC, Fernandez S, Garg S, Beacham L, Holtz TH, Curlin ME, Dawood F, Olsen SJ, Gangappa S, Stevens J, Sambhara S.

J Infect Dis. 2019 Jul 31;220(5):743-751. doi: 10.1093/infdis/jiz205.

PMID:
31045222
2.

Kinetics of antibody response to influenza vaccination in renal transplant recipients.

Gangappa S, Wrammert J, Wang D, Li ZN, Liepkalns JS, Cao W, Chen J, Levine MZ, Stevens J, Sambhara S, Begley B, Mehta A, Pearson TC, Ahmed R, Larsen CP.

Transpl Immunol. 2019 Apr;53:51-60. doi: 10.1016/j.trim.2019.01.001. Epub 2019 Jan 18.

PMID:
30664927
3.

An ELISA-based method for detection of rabies virus nucleoprotein-specific antibodies in human antemortem samples.

Realegeno S, Niezgoda M, Yager PA, Kumar A, Hoque L, Orciari L, Sambhara S, Olson VA, Satheshkumar PS.

PLoS One. 2018 Nov 7;13(11):e0207009. doi: 10.1371/journal.pone.0207009. eCollection 2018.

4.

Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.

Sayedahmed EE, Kumari R, Shukla S, Hassan AO, Mohammed SI, York IA, Gangappa S, Sambhara S, Mittal SK.

Vaccine. 2018 Oct 29;36(45):6744-6751. doi: 10.1016/j.vaccine.2018.09.031. Epub 2018 Sep 25.

PMID:
30266488
5.

A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose.

Sayedahmed EE, Hassan AO, Kumari R, Cao W, Gangappa S, York I, Sambhara S, Mittal SK.

Mol Ther Methods Clin Dev. 2018 Jul 17;10:210-222. doi: 10.1016/j.omtm.2018.07.007. eCollection 2018 Sep 21.

6.

Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI® induces enhanced serological, cellular and protective immune responses.

Cao W, Mishina M, Amoah S, Mboko WP, Bohannon C, McCoy J, Mittal SK, Gangappa S, Sambhara S.

Drug Deliv. 2018 Nov;25(1):773-779. doi: 10.1080/10717544.2018.1450909.

7.

Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.

Hassan AO, Amen O, Sayedahmed EE, Vemula SV, Amoah S, York I, Gangappa S, Sambhara S, Mittal SK.

PLoS One. 2017 Oct 12;12(10):e0186244. doi: 10.1371/journal.pone.0186244. eCollection 2017.

8.
9.

Vaccine approaches conferring cross-protection against influenza viruses.

Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK.

Expert Rev Vaccines. 2017 Nov;16(11):1141-1154. doi: 10.1080/14760584.2017.1379396. Epub 2017 Sep 19. Review.

10.

Critical role of RIG-I and MDA5 in early and late stages of Tulane virus infection.

Chhabra P, Ranjan P, Cromeans T, Sambhara S, Vinjé J.

J Gen Virol. 2017 May;98(5):1016-1026. doi: 10.1099/jgv.0.000769. Epub 2017 May 22.

11.

Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.

Cao W, Kim JH, Reber AJ, Hoelscher M, Belser JA, Lu X, Katz JM, Gangappa S, Plante M, Burt DS, Sambhara S.

Vaccine. 2017 Jun 5;35(25):3318-3325. doi: 10.1016/j.vaccine.2017.05.004. Epub 2017 May 9.

PMID:
28499553
12.

Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GARP Complex in Extracellular Virus Formation.

Realegeno S, Puschnik AS, Kumar A, Goldsmith C, Burgado J, Sambhara S, Olson VA, Carroll D, Damon I, Hirata T, Kinoshita T, Carette JE, Satheshkumar PS.

J Virol. 2017 May 12;91(11). pii: e00011-17. doi: 10.1128/JVI.00011-17. Print 2017 Jun 1.

13.

Influenza virus exploits tunneling nanotubes for cell-to-cell spread.

Kumar A, Kim JH, Ranjan P, Metcalfe MG, Cao W, Mishina M, Gangappa S, Guo Z, Boyden ES, Zaki S, York I, García-Sastre A, Shaw M, Sambhara S.

Sci Rep. 2017 Jan 6;7:40360. doi: 10.1038/srep40360.

14.

Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease.

Kim JH, Reber AJ, Kumar A, Ramos P, Sica G, Music N, Guo Z, Mishina M, Stevens J, York IA, Jacob J, Sambhara S.

Sci Rep. 2016 Nov 16;6:37341. doi: 10.1038/srep37341.

15.

Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.

Reber AJ, Kim JH, Coleman LA, Spencer SM, Chung JR, Chen J, Gargiullo P, Sundaram ME, Belongia EA, Shay DK, Katz JM, Sambhara S.

J Infect Dis. 2016 Nov 15;214(10):1477-1486. Epub 2016 Aug 28.

16.

Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season.

Kim JH, Mishina M, Chung JR, Cole KS, Nowalk MP, Martin JM, Spencer S, Flannery B, Zimmerman RK, Sambhara S.

J Infect Dis. 2016 Oct 1;214(7):1030-8. doi: 10.1093/infdis/jiw311. Epub 2016 Aug 17.

17.

High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses.

Kim JH, Talbot HK, Mishina M, Zhu Y, Chen J, Cao W, Reber AJ, Griffin MR, Shay DK, Spencer SM, Sambhara S.

Vaccine. 2016 Aug 31;34(38):4594-4601. doi: 10.1016/j.vaccine.2016.07.018. Epub 2016 Jul 26.

18.

Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice.

Liepkalns JS, Pandey A, Hofstetter AR, Kumar A, Jones EN, Cao W, Liu F, Levine MZ, Sambhara S, Gangappa S.

Viral Immunol. 2016 Oct;29(8):487-493. Epub 2016 Jul 22.

19.

Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells.

Coleman LA, Mishina M, Thompson M, Spencer SM, Reber AJ, Davis WG, Cheng PY, Belongia EA, Talbot HK, Sundaram ME, Griffin MR, Shay DK, Sambhara S.

Oncotarget. 2016 Jun 14;7(24):35512-35521. doi: 10.18632/oncotarget.9398.

20.

An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.

Cao W, Davis WG, Kim JH, De La Cruz JA, Taylor A, Hendrickson GR, Kumar A, Ranjan P, Lyon LA, Katz JM, Gangappa S, Sambhara S.

Nanomedicine. 2016 Oct;12(7):1909-1917. doi: 10.1016/j.nano.2016.04.005. Epub 2016 Apr 23.

21.

RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.

Cao W, Liepkalns JS, Kamal RP, Reber AJ, Kim JH, Hofstetter AR, Amoah S, Stevens J, Ranjan P, Gangappa S, York IA, Sambhara S.

Cell Immunol. 2016 Jun-Jul;304-305:55-8. doi: 10.1016/j.cellimm.2016.04.004. Epub 2016 Apr 9.

22.

NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice.

Hofstetter AR, De La Cruz JA, Cao W, Patel J, Belser JA, McCoy J, Liepkalns JS, Amoah S, Cheng G, Ranjan P, Diebold BA, Shieh WJ, Zaki S, Katz JM, Sambhara S, Lambeth JD, Gangappa S.

PLoS One. 2016 Feb 24;11(2):e0149864. doi: 10.1371/journal.pone.0149864. eCollection 2016.

23.

A highly immunogenic vaccine against A/H7N9 influenza virus.

Cao W, Liepkalns JS, Hassan AO, Kamal RP, Hofstetter AR, Amoah S, Kim JH, Reber AJ, Stevens J, Katz JM, Gangappa S, York IA, Mittal SK, Sambhara S.

Vaccine. 2016 Feb 3;34(6):744-9. doi: 10.1016/j.vaccine.2015.12.062. Epub 2016 Jan 4.

24.

Human Heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins.

Batra J, Tripathi S, Kumar A, Katz JM, Cox NJ, Lal RB, Sambhara S, Lal SK.

Sci Rep. 2016 Jan 11;6:19063. doi: 10.1038/srep19063.

25.

Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains.

Kim JH, Liepkalns J, Reber AJ, Lu X, Music N, Jacob J, Sambhara S.

Vaccine. 2016 Jan 20;34(4):495-502. doi: 10.1016/j.vaccine.2015.11.077. Epub 2015 Dec 17.

26.

Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.

Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S.

Open Forum Infect Dis. 2015 Apr 15;2(2):ofv052. doi: 10.1093/ofid/ofv052. eCollection 2015 Apr.

27.

Increased Dietary Salt Intake Does Not Influence Influenza A Virus-Induced Disease Severity in Mice.

Amoah S, Cao W, Ranjan P, Greer P, Shieh WJ, Zaki SR, Katz JM, Sambhara S, Gangappa S.

Viral Immunol. 2015 Nov;28(9):532-7. doi: 10.1089/vim.2015.0037. Epub 2015 Aug 18.

28.

A Newly Emerged Swine-Origin Influenza A(H3N2) Variant Dampens Host Antiviral Immunity but Induces Potent Inflammasome Activation.

Cao W, Mishina M, Ranjan P, De La Cruz JA, Kim JH, Garten R, Kumar A, García-Sastre A, Katz JM, Gangappa S, Sambhara S.

J Infect Dis. 2015 Dec 15;212(12):1923-9. doi: 10.1093/infdis/jiv330. Epub 2015 Jun 11.

29.

NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection.

Ranjan P, Singh N, Kumar A, Neerincx A, Kremmer E, Cao W, Davis WG, Katz JM, Gangappa S, Lin R, Kufer TA, Sambhara S.

Eur J Immunol. 2015 Mar;45(3):758-72. doi: 10.1002/eji.201344412. Epub 2014 Dec 23.

30.

Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, Murali-Krishna K.

J Virol. 2014 Dec;88(24):13990-4001. doi: 10.1128/JVI.02273-14. Epub 2014 Sep 24.

31.

Influenza A viral nucleoprotein interacts with cytoskeleton scaffolding protein α-actinin-4 for viral replication.

Sharma S, Mayank AK, Nailwal H, Tripathi S, Patel JR, Bowzard JB, Gaur P, Donis RO, Katz JM, Cox NJ, Lal RB, Farooqi H, Sambhara S, Lal SK.

FEBS J. 2014 Jul;281(13):2899-914. doi: 10.1111/febs.12828. Epub 2014 Jun 2.

32.

Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.

Ross TM, Lin CJ, Nowalk MP, Huang HH, Spencer SM, Shay DK, Sambhara S, Sundaram ME, Friedrich T, Sauereisen S, Bloom CE, Zimmerman RK.

Hum Vaccin Immunother. 2014;10(5):1195-203. doi: 10.4161/hv.28313. Epub 2014 Mar 10.

33.

Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time.

Vemula SV, Amen O, Katz JM, Donis R, Sambhara S, Mittal SK.

Virus Res. 2013 Dec 26;178(2):398-403. doi: 10.1016/j.virusres.2013.09.013. Epub 2013 Sep 17.

34.

Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis.

Gao R, Bhatnagar J, Blau DM, Greer P, Rollin DC, Denison AM, Deleon-Carnes M, Shieh WJ, Sambhara S, Tumpey TM, Patel M, Liu L, Paddock C, Drew C, Shu Y, Katz JM, Zaki SR.

Am J Pathol. 2013 Oct;183(4):1258-1268. doi: 10.1016/j.ajpath.2013.06.023. Epub 2013 Aug 11.

PMID:
23938324
35.

Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice.

Vemula SV, Pandey A, Singh N, Katz JM, Donis R, Sambhara S, Mittal SK.

Virus Res. 2013 Oct;177(1):55-61. doi: 10.1016/j.virusres.2013.07.008. Epub 2013 Jul 23.

36.

Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.

Vemula SV, Ahi YS, Swaim AM, Katz JM, Donis R, Sambhara S, Mittal SK.

PLoS One. 2013 Apr 30;8(4):e62496. doi: 10.1371/journal.pone.0062496. Print 2013.

37.

Influenza A virus nucleoprotein induces apoptosis in human airway epithelial cells: implications of a novel interaction between nucleoprotein and host protein Clusterin.

Tripathi S, Batra J, Cao W, Sharma K, Patel JR, Ranjan P, Kumar A, Katz JM, Cox NJ, Lal RB, Sambhara S, Lal SK.

Cell Death Dis. 2013 Mar 28;4:e562. doi: 10.1038/cddis.2013.89.

38.

RIG-I goes beyond naked recognition.

Bowzard JB, Ranjan P, Sambhara S.

Cell Host Microbe. 2013 Mar 13;13(3):247-9. doi: 10.1016/j.chom.2013.02.012.

39.

Improving influenza vaccines.

Sambhara S, Rappuoli R.

Expert Rev Vaccines. 2012 Aug;11(8):871-2. No abstract available.

PMID:
23002964
40.

Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice.

Taylor AK, Cao W, Vora KP, De La Cruz J, Shieh WJ, Zaki SR, Katz JM, Sambhara S, Gangappa S.

J Infect Dis. 2013 Feb 1;207(3):501-10. doi: 10.1093/infdis/jis527. Epub 2012 Sep 4.

PMID:
22949306
41.

Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity.

Onomoto K, Jogi M, Yoo JS, Narita R, Morimoto S, Takemura A, Sambhara S, Kawaguchi A, Osari S, Nagata K, Matsumiya T, Namiki H, Yoneyama M, Fujita T.

PLoS One. 2012;7(8):e43031. doi: 10.1371/journal.pone.0043031. Epub 2012 Aug 13. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/dcd836ee-9e23-4538-acb7-450560ba5c1d. PLoS One. 2013;8(4). doi:10.1371/annotation/14a6b875-ed9d-41ae-8ce6-52e8c5c7f85b.

42.

Strategies to alleviate original antigenic sin responses to influenza viruses.

Kim JH, Davis WG, Sambhara S, Jacob J.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13751-6. doi: 10.1073/pnas.0912458109. Epub 2012 Aug 6.

43.

Rapid differentiation of monocytes into type I IFN-producing myeloid dendritic cells as an antiviral strategy against influenza virus infection.

Cao W, Taylor AK, Biber RE, Davis WG, Kim JH, Reber AJ, Chirkova T, De La Cruz JA, Pandey A, Ranjan P, Katz JM, Gangappa S, Sambhara S.

J Immunol. 2012 Sep 1;189(5):2257-65. doi: 10.4049/jimmunol.1200168. Epub 2012 Aug 1.

44.
45.

Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S.

Aging Dis. 2012 Feb;3(1):68-90. Epub 2011 Sep 30.

46.

The 3' untranslated regions of influenza genomic sequences are 5'PPP-independent ligands for RIG-I.

Davis WG, Bowzard JB, Sharma SD, Wiens ME, Ranjan P, Gangappa S, Stuchlik O, Pohl J, Donis RO, Katz JM, Cameron CE, Fujita T, Sambhara S.

PLoS One. 2012;7(3):e32661. doi: 10.1371/journal.pone.0032661. Epub 2012 Mar 15.

47.

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.

Pandey A, Singh N, Vemula SV, Couëtil L, Katz JM, Donis R, Sambhara S, Mittal SK.

PLoS One. 2012;7(3):e33428. doi: 10.1371/journal.pone.0033428. Epub 2012 Mar 14.

48.

Influenza A virus neuraminidase protein enhances cell survival through interaction with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) protein.

Gaur P, Ranjan P, Sharma S, Patel JR, Bowzard JB, Rahman SK, Kumari R, Gangappa S, Katz JM, Cox NJ, Lal RB, Sambhara S, Lal SK.

J Biol Chem. 2012 Apr 27;287(18):15109-17. doi: 10.1074/jbc.M111.328070. Epub 2012 Mar 6.

49.

Improving immunogenicity and effectiveness of influenza vaccine in older adults.

Cao W, Kim JH, Chirkova T, Reber AJ, Biber R, Shay DK, Sambhara S.

Expert Rev Vaccines. 2011 Nov;10(11):1529-37. doi: 10.1586/erv.11.137. Review.

PMID:
22043953
50.

Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice.

Jeisy-Scott V, Davis WG, Patel JR, Bowzard JB, Shieh WJ, Zaki SR, Katz JM, Sambhara S.

PLoS One. 2011;6(9):e25242. doi: 10.1371/journal.pone.0025242. Epub 2011 Sep 23.

Supplemental Content

Loading ...
Support Center